by Sermonix Pharmaceuticals | Dec 12, 2023 | News
Most patients minimized or hid side effects from their health care providers for fear of negative perceptions, reduced treatment efficacy, or being taken off a drug or out of a clinical trial Sexual dysfunction was the most commonly cited side effect with a negative...
by Sermonix Pharmaceuticals | Dec 12, 2023 | News
COLUMBUS, Ohio, Dec. 12, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, today broadly shared the...
by Sermonix Pharmaceuticals | Dec 11, 2023 | News
COLUMBUS, Ohio, Dec. 11, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced that results...
by Sermonix Pharmaceuticals | Nov 28, 2023 | News
COLUMBUS, Ohio, Nov. 28, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced that it had...
by Sermonix Pharmaceuticals | Nov 8, 2023 | News
Dr. Einav Nili Gal-Yam, head of the Breast Oncology Institute at Chaim Sheba Medical Center, was the principal investigator COLUMBUS, Ohio, Nov. 06, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing...
by Sermonix Pharmaceuticals | Oct 2, 2023 | News
Results showed that younger age, non-visceral disease, prior tamoxifen and a longer total duration of AI use may be associated with higher baseline vaginal and/or vulvar symptomatology Findings were presented in a poster at The Menopause Society 2023 Annual Meeting...
Recent Comments